Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
March 17th, 2022
We present a protocol to induce and phenotype an acute right heart failure in a large animal model with chronic pulmonary hypertension. This model can be used to test therapeutic interventions, to develop right heart metrics or to improve the understanding of acute right heart failure pathophysiology.
Overview
This article presents a protocol for inducing and phenotyping acute right heart failure in a large animal model with chronic pulmonary hypertension. This model aims to enhance the understanding of acute right heart failure pathophysiology and test therapeutic interventions.
Key Study Components
Area of Science
- Cardiovascular physiology
- Pathophysiology of heart failure
- Animal models in biomedical research
Background
- Acute right heart failure is a critical condition often associated with pulmonary hypertension.
- Understanding its pathophysiology is essential for developing effective treatments.
- Large animal models provide a more relevant physiological context compared to smaller models.
- This study focuses on a reproducible method to induce this condition in a controlled setting.
Purpose of Study
- To establish a reliable model for studying acute right heart failure.
- To facilitate the testing of new therapeutic strategies.
- To improve the understanding of the underlying mechanisms of right heart failure.
Methods Used
- Induction of acute right heart failure through volume and pressure overload.
- Use of central venous catheterization for monitoring.
- Insertion of a catheter into the femoral artery for blood pressure measurement.
- Reproducibility of the model to mimic clinical conditions.
Main Results
- The model successfully replicates the pathophysiological aspects of acute right heart failure.
- Therapeutic interventions can be tested effectively using this model.
- Provides insights into the mechanisms of right heart failure.
- Facilitates the development of right heart metrics.
Conclusions
- This model is a valuable tool for research in acute right heart failure.
- It enhances the understanding of the disease and potential treatments.
- Future studies can build upon this protocol to explore various therapeutic avenues.
Frequently Asked Questions
Executive Industry Relevance
Dynamic phenotyping of acute right heart failure (ARHF) in a large animal model of chronic thromboembolic pulmonary hypertension enables translationally relevant interrogation of right ventricular adaptation and decompensation. This model provides a platform for quantitative assessment of hemodynamic compromise and therapeutic intervention, supporting predictive confidence in target validation and mechanistic de-risking for cardiovascular drug discovery. The approach bridges preclinical discovery and translational research by enabling direct comparison of invasive and non-invasive cardiac function metrics.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of right ventricular pathophysiology under controlled volume and pressure overload conditions.
- Supports mechanistic de-risking by quantifying adaptive versus maladaptive cardiac responses.
- Facilitates functional target validation for interventions aimed at right heart failure.
Screening & Assay Development
- Provides validated pressure-volume loop and echocardiographic endpoints for downstream screening workflows.
- Enables reproducible, quantitative assessment of right ventricular function for assay standardization.
- Supports screening readiness by establishing robust, scalable phenotyping protocols.
Translational & Preclinical Research
- Aligns preclinical endpoints with clinically relevant hemodynamic and imaging biomarkers.
- Enables risk-adjusted advancement decisions by modeling acute decompensation in chronic disease context.
- Supports validation of non-invasive imaging parameters for translational continuity.
Pipeline & Workflow Integration
This model integrates from early discovery through preclinical validation, supporting lead identification and translational biomarker development in right heart failure research.
- Discovery Biology: Quantifies right ventricular adaptation and failure, informing hypothesis testing and pathway clarification.
- Screening: Delivers standardized, quantitative outputs for functional cardiac assessment.
- Analytics: Provides pressure-volume loop and echocardiographic data for comparative analysis of interventions.
- Translational Research: Bridges invasive and non-invasive endpoints for biomarker alignment and preclinical-to-clinical continuity.
- Enterprise Reuse: Establishes a reusable large animal platform for cardiovascular therapeutic evaluation.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in right heart failure models.
- Operational Value: Standardizes phenotyping protocols and enables reproducible, scalable data acquisition.
- Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk in cardiovascular portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of right heart failure therapeutics.
Implementation Considerations
- Requires expertise in large animal surgery, hemodynamic monitoring, and cardiac imaging.
- Demands access to pressure-volume loop workstations, echocardiography, and fluoroscopy infrastructure.
- Necessitates cross-team standardization of phenotyping and data acquisition protocols.
- Adaptation to other disease models or species may require protocol optimization.
- Model learning curve and animal mortality highlight the need for procedural proficiency.
Biopharma FAQs
Chapters in this video
0:04
Introduction
0:39
Catheter Placement
1:44
Echocardiography
2:19
Right Heart Catheterization and Pressure Volume Loop Acquisition
3:20
Acute Right Heart Failure Induction
3:58
Pressure Overload with Iterative Pulmonary Embolism Induction
4:40
Systemic Hemodynamic Restoration
5:30
Results: Representative Acute Right Heart Failure Phenotype Analyses
7:07
Conclusion
